Ignite Creation Date:
2024-05-05 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00109070
Status:
COMPLETED
Last Update Posted:
2013-06-21
First Post:
2005-04-22
Brief Title:
A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal Cancer
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
A Phase III Multicenter Randomized Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF Bevacizumab in Combination With Standard Chemotherapy in Subjects With Metastatic Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter Phase III randomized active-controlled trial to evaluate the efficacy and safety of rhuMAb VEGF Avastin added to the standard first-line chemotherapy used to treat metastatic colorectal cancer This trial will enroll approximately 900 subjects with histologically confirmed previously untreated bi-dimensionally measurable metastatic colorectal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None